Collagen biology and non-invasive biomarkers of liver fibrosis

Research output: Contribution to journalReviewResearchpeer-review

  • Morten A. Karsdal
  • Samuel J. Daniels
  • Signe Holm Nielsen
  • Cecilie Bager
  • Daniel G.K. Rasmussen
  • Rohit Loomba
  • Rambabu Surabattula
  • Ida Falk Villesen
  • Yi Luo
  • Diane Shevell
  • Natasja S. Gudmann
  • Mette J. Nielsen
  • Jacob George
  • Rose Christian
  • Diana J. Leeming
  • Detlef Schuppan

There is an unmet need for high-quality liquid biomarkers that can safely and reproducibly predict the stage of fibrosis and the outcomes of chronic liver disease (CLD). The requirement for such markers has intensified because of the high global prevalence of diseases such as non-alcoholic fatty liver disease (NAFLD). In particular, there is a need for diagnostic and prognostic tools, as well as predictive biomarkers that reflect the efficacy of interventions, as described by the BEST criteria (Biomarkers, EndpointS, and other Tools Resource). This review covers the various liver collagens, their functional role in tissue homeostasis and delineates the common nomenclature for biomarkers based on BEST criteria. It addresses the common confounders affecting serological biomarkers, and describes defined collagen epitope biomarkers that originate from the dynamic processes of extracellular matrix (ECM) remodelling during liver injury.

Original languageEnglish
JournalLiver International
Volume40
Issue number4
Pages (from-to)736-750
ISSN1478-3223
DOIs
Publication statusPublished - 2020

Bibliographical note

Publisher Copyright:
© 2020 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd

    Research areas

  • biomarker, cirrhosis, collagen, fibrogenesis, fibrolysis, fibrosis, HBV, HCV, liver, monitoring, NAFLD, NASH, non-invasive, peptide, plasma, procollagen, serum, treatment

ID: 270628556